Tern Valuation Multiples

Tern is valued at $11M as of November 2026, a 152.4x revenue multiple. In the last fiscal year, Tern revenue was $73K and Tern EBITDA was ($7M).

See full Tern profile

Tern Overview

About Tern

Tern PLC is an Alternative Investment Market, quoted investment company specialising in investing in private software companies, predominantly in the Internet of Things (IoT) domain.


Founded

2004

HQ

United Kingdom

Employees

3

Sectors

Financials (Last FY)

Revenue: $73K
EBITDA: ($7M)

EV

$11M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tern Financials

Tern reported last fiscal year revenue of $73K and negative EBITDA of ($7M).

In the same fiscal year, Tern generated ($7M) in EBITDA losses and had net loss of ($7M).


Tern P&L

In the most recent fiscal year, Tern reported revenue of $73K and EBITDA of ($7M).

Tern is unprofitable as of last fiscal year, with EBITDA margin of (9503%) and net margin of (9424%).

See analyst estimates for Tern
Last FY202320242025202620272028
Revenue$73K$270K$24K$73K
EBITDA($7M)($2M)($2M)($7M)
EBITDA Margin(9503%)(768%)(6796%)(9503%)
EBIT Margin(1800%)(768%)(6796%)(1800%)
Net Profit($7M)($17M)($5M)($7M)
Net Margin(9424%)(6328%)(21676%)(9424%)
Net Debt$178K---

Financial data powered by Morningstar, Inc.

Tern Stock Performance

Tern has current market cap of $11M, and enterprise value of $11M.

Market Cap Evolution


Tern's stock price is $0.01.

Tern share price decreased by 5.1% in the last 30 days, and increased by 159.4% in the last year.

Tern has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Tern
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$11M$11M-0.0%-5.1%-23.0%159.4%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tern Valuation Multiples

Tern trades at 152.4x EV/Revenue multiple, and (1.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Tern

Tern Financial Valuation Multiples

As of November 8, 2026, Tern has market cap of $11M and EV of $11M.

Tern has a P/E ratio of (1.6x).

Last FY202320242025202620272028
EV/Revenue152.4x41.0xn/m152.4x
EV/EBITDA(1.6x)(5.3x)(6.9x)(1.6x)
EV/EBIT(8.5x)(5.3x)(6.9x)(8.5x)
P/E(1.6x)(0.6x)(2.2x)(1.6x)
EV/FCF(5.2x)(7.7x)(5.2x)(5.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tern Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Tern Margins & Growth Rates

In the most recent fiscal year, Tern reported EBITDA margin of (9503%) and net margin of (9424%).

See estimated margins and future growth rates for Tern

Tern Margins

Last FY20242025202720282029
EBITDA Margin(9503%)(6796%)(9503%)
EBIT Margin(1800%)(6796%)(1800%)
Net Margin(9424%)(21676%)(9424%)
FCF Margin(2917%)(9024%)(2917%)

Tern Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(91%)208%
EBITDA Growth(23%)331%
EBIT Growth(23%)(18%)
Net Profit Growth(70%)34%
FCF Growth47%(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Tern Operational KPIs

Tern's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Tern
Last FY202320242025202620272028
Revenue per Employee$0.0M---
Opex per Employee$0.5M---
G&A Expenses to Revenue1867%865%6879%1867%
Opex to Revenue1900%868%6896%1900%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Tern Competitors

Tern competitors include KDventures, Clal Biotechnology, Unfold.vc, Almeda Ventures, Netcapital, BTC Health, Bio Meat Foodtech, Scalare Partners Holdings, CodeLab Capital and MKB Nedsense.

Most Tern public comparables operate across PE & VC.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
KDventures$170K($20M)35.2x-(0.3x)-
Clal Biotechnology-($6M)--(2.6x)-
Unfold.vc($993K)($1M)(8.8x)-(7.0x)-
Almeda Ventures------
Netcapital$869K($28M)13.6x-(0.4x)-
BTC Health$68K($414K)160.6x-(26.3x)-
Bio Meat Foodtech------
Scalare Partners Holdings$10M$3M3.2x-10.2x-

This data is available for Pro users. Sign up to see all Tern competitors and their valuation data.

Start Free Trial

Acquisitions by Tern

Tern has acquired 2 companies to date.

Last acquisition by Tern was on May 26th 2016. Tern acquired Flexiant for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Tern

Flexiant
Cryptosoft
Description
Flexiant is a cloud orchestration software provider targeting service providers with its vendor-agnostic platform supporting multiple hypervisors. Flexiant Cloud Orchestrator includes metering, billing, and reseller features to accelerate service launches.
Cryptosoft is a data security platform for Internet of Things devices, protecting data at rest and in transit. San Francisco-headquartered with offices in Boston and Thames Valley, UK, it integrates with ThingWorx and AWS IoT. Deployments reduce attack surfaces in industrial sensors and smart grids. Partnerships cover semiconductor firms for embedded encryption.
HQ CountryUnited KingdomUnited Kingdom
HQ City
London
Bracknell
Deal Date26 May 201615 Sep 2014
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Tern acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Tern

Tern has invested in 8 companies to date.

Latest investment by Tern was on July 28th 2026. Tern invested in Talking Medicines in their $157K Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Tern

Talking Medicines
Talking Medicines
Device Authority
Talking Medicines
Description
Talking Medicines is a social intelligence platform analyzing patient feedback for pharmaceutical companies using AI and natural language processing in PatientMetRx. Its Drug-GPT tool queries curated data from patients and healthcare professionals. The service targets the $30 billion pharmaceutical advertising sector to refine marketing strategies.
Talking Medicines is a social intelligence platform analyzing patient feedback for pharmaceutical companies using AI and natural language processing in PatientMetRx. Its Drug-GPT tool queries curated data from patients and healthcare professionals. The service targets the $30 billion pharmaceutical advertising sector to refine marketing strategies.
Device Authority is a UK-headquartered provider of IoT security platforms featuring automated device provisioning, key management, and policy enforcement. With a development center in San Ramon, California, it delivers KeyScaler software for scalable credential lifecycle management. The company addresses security in industrial, healthcare, and automotive sectors compliant with standards like NIST. Founded from a 2014 spin-out, Device Authority serves global enterprises with dynamic encryption solutions.
Talking Medicines is a social intelligence platform analyzing patient feedback for pharmaceutical companies using AI and natural language processing in PatientMetRx. Its Drug-GPT tool queries curated data from patients and healthcare professionals. The service targets the $30 billion pharmaceutical advertising sector to refine marketing strategies.
HQ CountryUnited KingdomUnited KingdomUnited KingdomUnited Kingdom
HQ City
Glasgow
Glasgow
Reading
Glasgow
Deal Date28 Jul 202625 May 202622 May 20261 Feb 2024
RoundSeedUndisclosed stageUndisclosed stageSeed
Raised$157K$400K$280K$506K
InvestorsTernTernTernTern
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Tern investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tern

When was Tern founded?Tern was founded in 2004.
Where is Tern headquartered?Tern is headquartered in United Kingdom.
How many employees does Tern have?As of today, Tern has over 3 employees.
Is Tern publicly listed?Yes, Tern is a public company listed on London Stock Exchange.
What is the stock symbol of Tern?Tern trades under TERN ticker.
When did Tern go public?Tern went public in 2006.
Who are competitors of Tern?Tern main competitors include KDventures, Clal Biotechnology, Unfold.vc, Almeda Ventures, Netcapital, BTC Health, Bio Meat Foodtech, Scalare Partners Holdings, CodeLab Capital, MKB Nedsense.
What is the current market cap of Tern?Tern's current market cap is $11M.
What is the current revenue of Tern?Tern's last fiscal year revenue is $73K.
What is the current EV/Revenue multiple of Tern?Current revenue multiple of Tern is 152.4x.
Is Tern profitable?No, Tern is not profitable.
How many companies Tern has acquired to date?As of November 2026, Tern has acquired 2 companies.
What was the largest acquisition by Tern?None of the M&A deals Tern has completed have disclosed valuations.
What companies Tern acquired?Tern acquired Cryptosoft and Flexiant.
In how many companies Tern has invested to date?As of November 2026, Tern has invested in 8 companies.
What was the last Tern investment?On 28th July 2026 Tern invested in Talking Medicines, participating in a $157K Seed round.
In what companies Tern invested in?Tern invested in FundamentalVR, Seal Software, Device Authority, Konektio, Talking Medicines, Wyld Networks, Flexiant, and Cryptosoft.

See public comps similar to Tern

Lists including Tern

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial